84 results about "Bcg bladder instillation" patented technology

The invention provides a prediction method and prediction system of an irresponsive gamma globulin Kawasaki disease. The method comprises the following steps that 21 original parameters of SVM model building are collected; the modelling original parameters comprise gender, age, fever time during treatment, clinical classification, CRP detection value, WBC value, PLT value, Hb value, ALT value, AST value, ALB value, gamma globulin using time and clinical diagnosed symptom indicators; the clinical diagnosed symptom indicators comprise conjunctival injection, erythra, cracked lips, a strawberry-like tongue, lymphadenectasis of a neck, hard and swollen hands and feet, digit peeling, crissum peeling and a red and swollen bacillus calmette-guerin scar; discretization is conducted on the original parameters to obtain SVM characteristic values corresponding to the original parameters; the SVM characteristic values are regarded as base data, a SVM model is built, and through the SVM model, a complication with irresponsive gamma globulin of the Kawasaki disease is predicted. By means of the prediction method and prediction system, early intervening treatment can be conducted on a patient, recovery of damage to a coronary artery is promoted, and the prediction method and prediction system have important significance and value on diagnosis and treatment of the Kawasaki disease in the future.

The invention relates to the field of molecular immunology. In recent years, tuberculosis revives in the global range. The emergence of drug-resistant strain always invalidates antibiotic therapy and the normally used tuberculosis vaccine-BCG vaccine also has limitations. The invention aims at screening the molecular simulation peptide of epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis, studying the protective immune response mechanism of the tuberculosis and further developing a novel concatenated poly epitope tuberculosis vaccine. The invention provides the molecular simulation peptide of the epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis; the amino acid sequence of the peptide is shown as SEQ ID NO:14. The invention further provides a screening method and the function of the peptide. Therefore, the molecular simulation peptide of the invention can more effectively prevent and control the generation and the development of the tuberculosis.